Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous thromboembolism in children: An international multicenter cohort study

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 72-79

  Young, G ^a   Becker, S ^b   During C ^c   Friedrichs, F ^d   Goldenberg, N ^e   Kenet, G ^f   Manco Johnson, M ^e   Scheffold, C ^c   Nowak Göttl, Ulrike ^c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e CHILDREN S HOSPITAL   (United States)

^f SHEBA MEDICAL CENTER   (Israel)

Author keywords

Children; Factor II G20210A; Factor V G1691A; Recurrence; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; GUANOSINE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; WARFARIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENDER; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEWBORN; ONSET AGE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN VARIANT; RADIODIAGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; VENOUS THROMBOEMBOLISM;

EID: 57749189116     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03198.x     Document Type: Article

References (41)

1. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, Grant R, Israels S, Jardine L, Luke B, Massicotte P, Silva M. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-7.
2. Schmidt B, Andrew M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-43.
3. Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: Two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76: F163-7.
4. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133: 770-6.
5. Monagle P, Adams M, Mahoney M, Ali K, Barnard D, Bernstein M, Brisson L, David M, Desai S, Scully MF, Halton J, Israels S, Jardine L, Leaker M, McCusker P, Silvia M, Wu J, Anderson R, Andrew M, Massicotte MP. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47: 763-6.
6. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: A prospective two-year registry in The Netherlands. J Pediatr 2001; 139: 676-81.
7. Andrew M. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 415-25.
8. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Cur Opin Hematol 2003; 10: 369-74.
9. Revel-Vilk S, Sharathkumar A, Massicotte P, Marzinotto V, Daneman A, Dix D, Chan A. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: A longitudinal study by ultrasound. J Thromb Haemost 2004; 2: 42-6.
10. Revel-Vilk S. Central venous line-related thrombosis in children. Acta Haematol 2006; 115: 201-6.
11. Journeycake J, Eshelman D, Buchanan GR. Post-thrombotic syndrome is uncommon in childhood cancer survivors. J Pediatr 2006; 148: 275-7.
12. Goldenberg NA. Long-term outcomes of venous thrombosis in children. Cur Opin Hematol 2005; 12: 370-6.
13. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
14. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
15. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
16. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
17. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-8.
18. Nuss R, Hays T, Manco-Johnson M. Childhood thrombosis. Pediatrics 1995; 96: 291-4.
19. Nowak-Göttl U, Koch HG, Aschka I, Kohlhase B, Vielhaber H, Kurlemann G, Oleszcuk-Raschke K, Kehl HG, Jürgens H, Schneppenheim R. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996; 92: 992-8.
20. Aschka I, Aumann V, Bergmann F, Budde U, Eberl W, Eckhof-Donovan S, Krey S, Nowak-Göttl U, Schobess R, Sutor AH, Wendisch J, Schneppenheim R. Prevalence of factor V Leiden in children with thrombo-embolism. Eur J Pediatr 1996; 155: 1009-14.
21. Uttenreuther-Fischer MM, Vetter B, Hellmann C, Otting U, Ziemer S, Hausdorf G, Gaedicke G, Kulozik AE. Paediatric thrombo-embolism: The influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Pediatr 1997; 156: 277-81.
22. Sifontes MT, Nuss R, Hunger SP, Waters J, Jacobsen LJ, Manco-Johnson M. Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. Am J Hematol 1998; 57: 29-32.
23. Hagstrom JN, Walter J, Bluebond-Langner R, Amatniek JC, Manno CS, High KA. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998; 133: 777-81.
24. Schobess R, Junker R, Auberger K, Münchow N, Burdach S, Nowak-Göttl U. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis - evidence of an age-dependent thrombotic onset in carriers of the factor V G1691A and prothrombin G20210A mutation. Eur J Pediatr 1999; 158: S105-8.
25. Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: A study in a single centre. Arch Dis Child 1999; 81: 176-8.
26. Junker R, Koch HG, Auberger K, Münchow N, Ehrenforth S, Nowak-Göttl U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999; 19: 2568-72.
27. Nowak-Göttl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N, Schobess R, Ehrenforth S; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-62.
28. Bonduel M, Hepner M, Sciuccati G, Pieroni G, Feliú-Torres A, Mardaraz C, Frontroth JP. Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism. Thromb Haemost 2002; 87: 972-7.
29. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1: 915-21.
30. Van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: Congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1: 2516-22.
31. Young G, Manco-Johnson M, Gill JC, Dimichele DM, Tarantino MD, Abshire T, Nugent DJ. Clinical manifestations of the prothrombin G20210A mutation in children: A pediatric coagulation consortium study. J Thromb Haemost 2003; 1: 958-62.
32. Atasay B, Arsan S, Günlemez A, Kemhali S, Akar N. Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: A study in a single center. Pediatr Hematol Oncol 2003; 20: 627-34.
33. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ; Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. New Engl J Med 2004; 351: 1081-8.
34. Brandão LR, Williams S, Kahr WH, Ryan C, Temple M, Chan AK. Exercise-induced deep vein thrombosis of the upper extremity. 2. A case series in children. Acta Haematol 2006; 115: 214-20.
35. Kreuz W, Stoll M, Junker R, Heinecke A, Schobess R, Kurnik K, Kelsch R, Nowak-Göttl U. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: Results of a multicenter study. Arterioscler Thromb Vasc Biol 2006; 26: 1901-6.
36. Kenet G, Kirkham F, Niederstadt T, Heinecke A, Saunders D, Stoll M, Brenner B, Bidlingmaier C, Heller C, Knöfler R, Schobess R, Zieger B, Sébire G, Nowak-Göttl U. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: A multicentre cohort study. Lancet Neurol 2007; 6: 595-603.
37. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 887S-962S.
38. Vossen CY, Walker ID, Svensson P, Souto JC, Scharrer I, Preston FE, Palaretti G, Pabinger I, van der Meer FJ, Makris M, Fontcuberta J, Conard J, Rosendaal FR. Recurrence rate after first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005; 25: 1992-7.
39. González-Porras JR, García-Sanz R, Alberca I, López ML, Balanzategui A, Gutierrez O, Lozano F, San Miguel J. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. Blood Coagul Fibrinolysis 2006; 17: 23-8.
40. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, Leone G. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C, and protein S. Haematologica 2006; 91: 695-8.
41. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: S454-545.